Download PDF
Semin Reprod Med 2014; 32(06): 433-437
DOI: 10.1055/s-0034-1384626
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Insights from the Women's Health Initiative: Individualizing Risk Assessment for Hormone Therapy Decisions

Robert A. Wild
1   Department of Obstetrics and Gynecology, Biostatistics and Epidemiology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma
,
JoAnn E. Manson
2   Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
16 October 2014 (online)

    Permissions and Reprints

Abstract

Identifying appropriate candidates for menopausal hormone therapy (HT) is challenging given the complex profile of risks and benefits associated with treatment. Most professional societies agree that HT should not be used for chronic disease prevention. Recent findings from the Women's Health Initiative and other randomized trials suggest that a woman's age, proximity to menopause, underlying cardiovascular risk factor status, and various biological characteristics may modify health outcomes with HT. An emerging body of evidence suggests that it may be possible to assess individual risk and therefore better predict who is more likely to have favorable outcomes versus adverse effects when taking HT. Thus, once a woman is identified as a potential candidate for HT due to moderate-to-severe menopausal symptoms or other indications, risk stratification may be an important tool for minimizing patient risk. This individualized approach holds great promise for improving the safety of HT. We review here the evidence for this approach, focusing on vascular health because of limited data on other outcomes. The ultimate goal of this research is to develop a personalized risk/benefit prediction model to be used when a woman seeks therapy for symptom management. Patient centered outcomes including quality of life and sense of well-being should also be incorporated and will directly impact the benefit: risk ratio and compliance. Additional research on hormone dose, formulation, and route of delivery will be important for improving this model.

Keywords

hormone therapy - risk - individualizing - estrogen - menopause
 

  • References

  • 1 North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012; 19: 257-271
    PubMedGoogle Scholar
  • 2 Santen RJ, Allred DC, Ardoin SP , et al; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95 (7) (Suppl. 01) s1-s66
    CrossrefPubMedGoogle Scholar
  • 3 Frank SM, Ziegler C, Kokot-Kierepa M, Maamari R, Nappi RE. Vaginal Health: Insights, Views & Attitudes (VIVA) survey - Canadian cohort. Menopause Int 2012;
    PubMedGoogle Scholar
  • 4 Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012; 19 (1) 109-117
    CrossrefPubMedGoogle Scholar
  • 5 Manson JE, Bassuk SS. The menopause transition and postmenopausal hormone therapy. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo L, , eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2011
    Google Scholar
  • 6 Writing Group on behalf of Workshop Consensus Group; International Menopause Society Consensus Statement. Aging, menopause, cardiovascular disease and HRT. Climacteric 2009; 12 (5) 368-377
    CrossrefPubMedGoogle Scholar
  • 7 Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013; 62 (Suppl. 01) S15-S19
    CrossrefPubMedGoogle Scholar
  • 8 Rossouw JE, Prentice RL, Manson JE , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297 (13) 1465-1477
    CrossrefPubMedGoogle Scholar
  • 9 Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?. Am J Epidemiol 2007; 166 (5) 511-517
    CrossrefPubMedGoogle Scholar
  • 10 Bray PF, Larson JC, Lacroix AZ , et al; Women's Health Initiative Investigators. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008; 101 (11) 1599-1605
    CrossrefPubMedGoogle Scholar
  • 11 Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308 (5728) 1583-1587
    CrossrefPubMedGoogle Scholar
  • 12 Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348 (7) 645-650
    CrossrefPubMedGoogle Scholar
  • 13 The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19 (1) 61-109
    CrossrefPubMedGoogle Scholar
  • 14 Rossouw JE, Anderson GL, Prentice RL , et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3) 321-333
    CrossrefPubMedGoogle Scholar
  • 15 Anderson GL, Limacher M, Assaf AR , et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291 (14) 1701-1712
    CrossrefPubMedGoogle Scholar
  • 16 Hsia J, Criqui MH, Herrington DM , et al; Women's Health Initiative Research Group. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. Am Heart J 2006; 152 (1) 170-176
    CrossrefPubMedGoogle Scholar
  • 17 Cushman M, Kuller LH, Prentice R , et al; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292 (13) 1573-1580
    CrossrefPubMedGoogle Scholar
  • 18 LaCroix AZ, Chlebowski RT, Manson JE , et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305 (13) 1305-1314
    CrossrefPubMedGoogle Scholar
  • 19 Wassertheil-Smoller S, Hendrix SL, Limacher M , et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289 (20) 2673-2684
    CrossrefPubMedGoogle Scholar
  • 20 Curb JD, Prentice RL, Bray PF , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166 (7) 772-780
    CrossrefPubMedGoogle Scholar
  • 21 Rossouw JE, Cushman M, Greenland P , et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med 2008; 168 (20) 2245-2253
    CrossrefPubMedGoogle Scholar
  • 22 Carpeggiani C, Coceani M, Landi P, Michelassi C, L'abbate A. ABO blood group alleles: A risk factor for coronary artery disease. An angiographic study. Atherosclerosis 2010; 211 (2) 461-466
    CrossrefPubMedGoogle Scholar
  • 23 Rossouw J, Bray P, Liu J , et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol 2011; 31 (2) 464-469
    CrossrefPubMedGoogle Scholar
  • 24 Barnabei VM, Cochrane BB, Aragaki AK , et al; Women's Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105 (5 Pt 1) 1063-1073
    CrossrefPubMedGoogle Scholar
  • 25 Ockene JK, Barad DH, Cochrane BB , et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294 (2) 183-193
    CrossrefPubMedGoogle Scholar
  • 26 Hays J, Ockene JK, Brunner RL , et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348 (19) 1839-1854
    CrossrefPubMedGoogle Scholar
  • 27 Brunner RL, Gass M, Aragaki A , et al; Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med 2005; 165 (17) 1976-1986
    CrossrefPubMedGoogle Scholar
  • 28 Brunner RL, Aragaki A, Barnabei V , et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010; 17 (5) 946-954
    CrossrefPubMedGoogle Scholar
  • 29 Manson JE. The Kronos Early Estrogen Prevention Study. Womens Health (Lond Engl) 2013; 9 (1) 9-11
    PubMedGoogle Scholar
  • 30 Canonico M, Oger E, Plu-Bureau G , et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115 (7) 840-845
    CrossrefPubMedGoogle Scholar
  • 31 Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: A nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013; 20 (3) 254-260
    PubMedGoogle Scholar